NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Bellicum Pharmaceuticals Inc (F: BPXA)

 
BPXA Technical Analysis
5
As on 11th Jul 2023 BPXA STOCK Price closed @ 0.27 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.28 & Strong Sell for SHORT-TERM with Stoploss of 1.44 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

BPXASTOCK Price

Open 0.27 Change Price %
High 0.27 1 Day -0.05 -15.62
Low 0.27 1 Week -0.04 -12.90
Close 0.27 1 Month -0.43 -61.43
Volume N/A 1 Year -1.03 -79.23
52 Week High 1.92 | 52 Week Low 0.11
 
F Germany Most Active Stocks
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
WDI 0.05 -37.50%
TOE 0.02 0.00%
 
F Germany Top Gainers Stocks
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
WPIA 6.22 871.88%
8S3B 1.73 620.83%
8S3B 1.73 620.83%
SY7P 0.07 600.00%
P9F1 1.75 326.83%
 
F Germany Top Losers Stocks
TINC 0.01 -99.92%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
LDB 1.71 -92.57%
AETG 0.25 -91.61%
AETG 0.25 -91.61%
 
 
BPXA
Daily Charts
BPXA
Intraday Charts
Whats New @
Bazaartrend
BPXA
Free Analysis
 
BPXA Important Levels Intraday
RESISTANCE0.27
RESISTANCE0.27
RESISTANCE0.27
RESISTANCE0.27
RESISTANCE0.27
RESISTANCE0.27
RESISTANCE0.27
RESISTANCE0.27
 
BPXA Forecast May 2024
4th UP Forecast1.1
3rd UP Forecast0.83
2nd UP Forecast0.67
1st UP Forecast0.5
1st DOWN Forecast0.04
2nd DOWN Forecast-0.13
3rd DOWN Forecast-0.29
4th DOWN Forecast-0.56
 
BPXA Weekly Forecast
4th UP Forecast0.46
3rd UP Forecast0.40
2nd UP Forecast0.36
1st UP Forecast0.32
1st DOWN Forecast0.22
2nd DOWN Forecast0.18
3rd DOWN Forecast0.14
4th DOWN Forecast0.08
 
BPXA Forecast2024
4th UP Forecast3.76
3rd UP Forecast2.64
2nd UP Forecast1.95
1st UP Forecast1.26
1st DOWN Forecast-0.72
2nd DOWN Forecast-1.41
3rd DOWN Forecast-2.1
4th DOWN Forecast-3.22
 
 
BPXA Other Details
Segment EQ
Market Capital 14360238.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
BPXA Address
BPXA
 
BPXA Latest News
 
Your Comments and Response on Bellicum Pharmaceuticals Inc
 
BPXA Business Profile
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes when administered after hematopoietic stem cell transplantation in the treatment of hematologic malignancies and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas. Address: 3730 Kirby Drive, Houston, TX, United States, 77098
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service